JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

Search

Pfizer

Открыт

СекторЗдравоохранение

24.52 -0.97

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

24.52

Макс.

24.75

Ключевые показатели

By Trading Economics

Доход

2.6B

3B

Продажи

-4B

14B

P/E

Средняя по отрасли

17.051

34.393

Прибыль на акцию

0.92

Дивидендная доходность

7.19

Рентабельность продаж

21.677

Сотрудники

81,000

EBITDA

2.5B

5.1B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+16.31% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

7.19%

2.54%

Следующий отчет о доходах

28 окт. 2025 г.

Дата следующей выплаты дивидендов

2 сент. 2025 г.

Следующая эксдивидендная дата

7 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-12B

134B

Предыдущая цена открытия

25.49

Предыдущая цена закрытия

24.52

Новостные настроения

By Acuity

39%

61%

125 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Pfizer График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 авг. 2025 г., 11:34 UTC

Отчет

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5 авг. 2025 г., 20:44 UTC

Отчет

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 авг. 2025 г., 18:20 UTC

Отчет

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 авг. 2025 г., 18:17 UTC

Отчет

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 авг. 2025 г., 16:04 UTC

Обсуждения рынка

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5 авг. 2025 г., 15:25 UTC

Отчет

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 авг. 2025 г., 13:56 UTC

Отчет

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 авг. 2025 г., 11:43 UTC

Отчет

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5 авг. 2025 г., 11:27 UTC

Отчет

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 авг. 2025 г., 10:57 UTC

Отчет

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5 авг. 2025 г., 10:55 UTC

Отчет

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 авг. 2025 г., 10:53 UTC

Отчет

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5 авг. 2025 г., 10:51 UTC

Отчет

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5 авг. 2025 г., 10:50 UTC

Отчет

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5 авг. 2025 г., 10:49 UTC

Отчет

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5 авг. 2025 г., 10:49 UTC

Отчет

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5 авг. 2025 г., 10:48 UTC

Отчет

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5 авг. 2025 г., 10:48 UTC

Отчет

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5 авг. 2025 г., 10:47 UTC

Отчет

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5 авг. 2025 г., 10:46 UTC

Отчет

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5 авг. 2025 г., 10:45 UTC

Отчет

Pfizer Raises 2025 EPS Guidance >PFE

5 авг. 2025 г., 10:45 UTC

Отчет

Pfizer 2Q EPS 51c >PFE

5 авг. 2025 г., 10:45 UTC

Отчет

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5 авг. 2025 г., 10:45 UTC

Отчет

Pfizer 2Q Adj EPS 78c >PFE

5 авг. 2025 г., 10:45 UTC

Отчет

Pfizer 2Q Rev $14.7B >PFE

5 авг. 2025 г., 10:45 UTC

Отчет

Pfizer Sees FY Rev $61B-$64B >PFE

4 авг. 2025 г., 15:26 UTC

Отчет

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30 июл. 2025 г., 18:36 UTC

Отчет

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9 июл. 2025 г., 09:17 UTC

Популярные акции

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10 июн. 2025 г., 12:18 UTC

Отчет

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Pfizer Прогноз

Целевая цена

By TipRanks

16.31% рост

Прогноз на 12 месяцев

Средняя 28.59 USD  16.31%

Максимум 33 USD

Минимум 24 USD

Основано на мнении 18 аналитиков Wall Street, спрогнозировавших целевые цены для Pfizer  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

18 ratings

6

Покупка

12

Удержание

0

Продажа

Техническая оценка

By Trading Central

22.855 / 23.85Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

125 / 374Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.